Dr Reddy's Lab gets nine observations after USFDA inspection of Hyderabad unit; Stock down 1%

Dr Reddy's Laboratories has informed to the exchanges that the United States Food & Drug Administration (USFDA) on Thursday completed a product specific Pre-Approval Inspection (PAI) at company's biologics manufacturing facility in Bachupally, Hyderabad.

As per the regulatory filing, the inspection was conducted from October 4, 2023 to October 12, 2023, the company informed.

Dr Reddy's said, “We have been issued a Form 483 with nine observations, which we will address within the stipulated timeline.”

On Friday mid-afternoon trade, shares of Dr Reddy's Lab were trading lower by 1.01% at Rs 5474.15 per share on the BSE.